NCT03080974 Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
| NCT ID | NCT03080974 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University of Louisville |
| Condition | Pancreatic Adenocarcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2017-08-14 |
| Primary Completion | 2028-06-01 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.
Eligibility Criteria
Inclusion Criteria: * ≥ 18 years if age * Diagnosed with stage III pancreatic cancer * Tumor is measurable * Glomerular Filtration Rate \> 60 m/L/min/1.73 m(2) * Willing and able to comply with the protocol requirements * Able to comprehend and have signed the informed consent to participate Exclusion Criteria: * Participating in another clinical trial for the treatment of cancer at time of screening * Are pregnant or currently breast feeding * Have a cardiac pacemaker or Implantable Cardioverter Defibrillator implanted that cannot be deactivated during the procedure * Have non-removable implants with metal parts within 1 cm of the target lesion * Had a myocardial infarction within 3 months prior to enrollment